Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Jun 4, 2021

Keywords

ClinConnect Summary

This clinical trial, called MiOx, is studying the effects of high-flow oxygen therapy on patients experiencing migraine attacks in the emergency department. Migraines are a common and painful condition that affects many people, often leading to emergency room visits. While high-flow oxygen therapy has been effective for other types of headaches, like cluster headaches, it hasn’t been thoroughly tested for migraines. Researchers believe that oxygen might help ease migraine symptoms without the side effects associated with traditional pain medications.

To participate in this study, you must be at least 18 years old and have a migraine that meets specific criteria. You also need to be enrolled in a French public health insurance plan. However, if you have chronic respiratory conditions like COPD, are pregnant, or have taken certain medications recently, you won’t be eligible. If you join the study, you'll receive either high-flow oxygen or a placebo (a treatment that looks like the real thing but doesn't contain any active medication) to see which is more effective at relieving your migraine. The trial aims to improve how migraines are treated in emergency settings while minimizing side effects, making it an important step toward better care for patients suffering from this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years old or more
• • Affiliated to a french public health insurance
• • ED admission for migraine evocative headache, regarding ICHD3 criterions
• • written informed consent
• Exclusion Criteria:
• • COPD or other chronic respiratory failure conditions
• • Pregnant or breastfeeding women or women of childbearing potential not using any means of contraception. A pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of her choice.
• • Under legal protection
• • Patients who have received treatment with triptan in the past 2 weeks
• • Patients who have consumed NSAIDs in the hour before the doctor's examination
• • State of migraine headache (crippling attack for more than 72 hours)